Tech Company Financing Transactions
Adiso Therapeutics Funding Round
Adiso Therapeutics secured a $60 million venture capital round on 3/10/2022. Investors included Morningside Group and private investors.
Transaction Overview
Company Name
Announced On
3/10/2022
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Undisclosed
Investors
Morningside Group (Lead Investor) (Jason Dinges)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
530 Virginia Rd. 300
Concord, MA 01742
USA
Concord, MA 01742
USA
Phone
Undisclosed
Website
Email Address
Overview
Adiso holds an inspiring vision to pursue bold and novel approaches to treating inflammation and the havoc it causes on the human body. Current treatment paradigms are far too often either inadequate to halt disease progression or burden the patient with significant safety concerns.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Scott Megaffin
Chief Operating Officer
Jennifer Locke
Chief Technical Officer
Bharat Dixit
VP - R & D
Chris Murphy
Browse more venture capital transactions:
Prev: 3/10/2022: Genomenon venture capital transaction
Next: 3/10/2022: Roofstock venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We report on all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs